Atrophic Vaginitis (Vaginal Atrophy) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Atrophic vaginitis is an inflammatory condition associated with vaginal atrophy caused by reduced estrogen levels, mainly occurring during menopause. Vaginal atrophy leads to thinning of the vaginal epithelium, decreased vaginal rugae and elasticity, and reduced vaginal secretions. It affects premenopausal women and up to 50% of postmenopausal women. The hypoestrogenic state responsible for atrophic vaginitis can result from natural menopause or be induced by medical interventions like surgery, radiation, chemotherapy, or certain medications such as Selective estrogen receptor modulators, Selective estrogen receptor degraders, and antigonadotropins. Lower estrogen levels cause alterations in the vaginal environment, disrupting the normal flora, leading to an overgrowth of skin and rectal pathogens due to decreased Lactobacillus spp. The diagnosis of atrophic vaginitis is typically based on the patient's history and specific physical examination findings. Symptoms include vaginal dryness, burning, pruritis, abnormal vaginal discharge, and painful intercourse. External genitalia signs may include atrophy of the labia majora and minora, dry labia, vulvar dermatoses, vulvar lesions, or sparse pubic hair. Differential diagnoses for atrophic vaginitis include various other conditions affecting the vulvovaginal area and urogenital function. Intravaginal estrogen therapy is the primary pharmacologic treatment, with options such as Conjugated estrogen cream, estradiol cream, estradiol tablet, estradiol vaginal ring, and estradiol transdermal patch. Low-dose local estrogen preparations are recommended to minimize systemic estrogen exposure. Risk factors for atrophic vaginitis include lack of vaginal births and smoking, which can worsen symptoms by reducing vaginal secretions due to vasoconstriction. If left untreated, atrophic vaginitis can lead to persistent itching, scarring from scratching, mucosal abrasions, and unresolved genitourinary complaints.

  • The prevalence of atrophic vaginitis varies, with an estimated 10% to 50% of postmenopausal women and 15% of premenopausal women experiencing symptoms of genitourinary syndrome.

 

Thelansis’s “Atrophic Vaginitis (Vaginal Atrophy) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrophic Vaginitis (Vaginal Atrophy) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Atrophic Vaginitis (Vaginal Atrophy) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Atrophic Vaginitis (Vaginal Atrophy) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Atrophic Vaginitis (Vaginal Atrophy) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more